カテゴリ： GlobalData, アメリカ, 企業調査

Genentech Inc：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Genentech Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C3442
◆発行会社（調査会社）：GlobalData
◆発行日：2018年8月
◆ページ数：99
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Genentech Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including bio-oncology, immunology, ophthalmology, metabolism, primary care, neurology, virology, hematology and specialty care. It has pipeline candidates in oncology, immunology, neuroscience, metabolism, infectious disease and ophthalmology. The company has research and manufacturing facilities in Vacaville, South San Francisco and Oceanside, California. Genentech is headquartered in South San Francisco, California, the US.

Genentech Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Genentech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Genentech Inc, Medical Devices Deals, 2012 to YTD 2018 13
Genentech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Genentech Inc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 17
Partnerships 18
Microbiotica Enters into Collaboration Agreement with Genentech 18
Tesaro Enters into Collaboration Agreement with Genentech 19
Lodo Therapeutics Enters into Agreement with Genentech 20
Tesaro Enters into Partnership with Genentech 21
Forty Seven Enters into Agreement with Genentech 22
Syndax Pharma Enters into Agreement with Genentech 23
DiCE Molecules Enters into Research Agreement with Genentech 24
Biothera Pharma Enters into Collaboration Agreement with Genentech 25
Epizyme Enters into Agreement with Genentech 26
Inovio Pharma Enters into Agreement with Genentech 27
Amunix Operating Enters into R&D Agreement with Genentech 28
BioNTech Enters into Agreement with Genentech 29
Gradalis Enters into Agreement with Genentech 30
G1 Therapeutics Enters into Agreement with Genentech 31
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 32
Charles River Laboratories International Extends Agreement with Genentech 33
BioLineRx Enters into Agreement with Genentech 34
Epizyme Enters into Agreement with Genentech 35
Astex Pharma Enters into Agreement with Genentech 36
Clovis Oncology Enters into Agreement with Genentech 37
Janssen Research & Development Enters into Agreement with Genentech 38
Kite Pharma Enters into Agreement with Genentech 39
PeptiDream Enters into Agreement with Genentech 40
Corvus Pharma Expands its Agreement with Genentech 41
Immune Design Enters into Clinical Trial Collaboration with Genentech 42
WaferGen Bio-systems Enters into Research Agreement with Genentech 43
23andMe Partners with Genentech 44
Genentech Enters into Research Agreement with NewLink Genetics 45
Ascendis Pharma Enters Into Collaboration Agreement with Genentech 46
RQx Pharma Enters Into Drug Discovery Agreement With Genentech 47
Ensemble Therapeutics Enters Into Drug Discovery Agreement With Genentech 48
Constellation Pharma Enters Into Co-Development Agreement With Genentech 49
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 50
Licensing Agreements 51
Genentech Enters into Licensing Agreement with Kineta Chronic Pain 51
Dermira Enters into Licensing Agreement with F. Hoffmann-La Roche and Genentech for Lebrikizumab 52
Mylan Enters into Licensing Agreement with Genentech and Roche 54
Genentech Enters into Licensing Agreement with Novimmune 55
Novogen Enters into Licensing Agreement with Genentech for GDC-0084 56
Genentech to Enter into Licensing Agreement with Hanmi Pharma 57
Denali Therapeutics Enters Into Licensing Agreement With Genentech 58
Genentech Enters into Licensing Agreement with Nimbus Therapeutics 59
Genentech Expands Licensing Agreement with Arvinas 60
Genentech Enters into Licensing Agreement with Almac Discovery 61
Phylogica Extends Licensing Agreement with Genentech 62
Genentech to Terminate Licensing Agreement with NewLink Genetics for NLG919 63
Coherus BioSciences Enters into Licensing Agreement with Genentech 65
Immunocore Enters Into Licensing And Research Agreement With Genentech For Cancer Drugs 66
Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 67
Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 68
Genentech Enters into Licensing Agreement with Carmot Therapeutics 69
Afraxis Enters Into Licensing Agreement With Genentech 70
AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 71
Acquisition 73
Noritsu Koki to Acquire 64.7% Stake in Genentech for USD27 Million 73
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology’s Spin-Out Companies 74
Genentech Inc – Key Competitors 75
Genentech Inc – Key Employees 76
Genentech Inc – Locations And Subsidiaries 77
Head Office 77
Other Locations & Subsidiaries 77
Recent Developments 78
Legal and Regulatory 78
Jan 11, 2017: New Drug Formulary Will Help Expedite Use of Agents in Clinical Trials 78
Jan 09, 2017: Genentech withdraws counterclaim against Exelixis 79
Government and Public Interest 80
May 14, 2018: Pivotal Study Validates Real-World Mortality Endpoint for Oncology Research 80
Jun 29, 2017: Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury 81
Product News 82
Oct 12, 2017: 10 SU2C Catalyst Clinical Trials Launched 82
06/15/2017: NICE reverses provisional decision and recommends Kadcyla (trastuzumab emtansine) for HER2-positive advanced breast cancer in England 84
06/12/2017: T-DM1 in HER2 Overexpressing, Amplified or Mutated Metastatic NSCLC 85
Product Approvals 87
Jun 15, 2017: Kadcyla new deal for breast cancer patients given green light in final draft guidance 87
Apr 10, 2017: Roche’s Kadcyla accepted for use in NHS Scotland 88
Clinical Trials 89
Apr 15, 2018: Genentech to Present Data on Investigational Anti-amyloid beta Antibodie Crenezumab 89
Dec 10, 2017: Phase II Data Showed Genentech’s Investigational Polatuzumab Vedotin Plus Bendamustine and Rituxan (BR) Increased Complete Response Rates Compared to BR Alone in Previously Treated Aggressive Lymphoma 90
Nov 30, 2017: Symphogen Receives Milestone Payment for Initiation of Phase 1b Trial in Infectious Disease 92
Nov 01, 2017: Data To Be Presented On Polatuzumab Vedotin At ASH 2017 Annual Meeting 93
Oct 24, 2017: AC Immune to Provide Scientific Update on Crenezumab at CTAD Conference 94
May 17, 2017: Data from Clinical Study of NewLink Genetics’ Navoximod to Be Presented at ASCO 2017 95
Apr 21, 2017: NewLink Genetics Provides Update on Pipeline Drug GDC-0919 at ASCO 96
Feb 28, 2017: AC Immune Partner Genentech To Start Second Phase 3 Clinical Trial For Alzheimer’s Therapy Crenezumab 97
Other Significant Developments 98
Feb 05, 2018: Inside Rx Provides Savings on Influenza Medications 98
Appendix 99
Methodology 99
About GlobalData 99
Contact Us 99
Disclaimer 99

List of Tables
Genentech Inc, Pharmaceuticals & Healthcare, Key Facts 2
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Genentech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Genentech Inc, Deals By Therapy Area, 2012 to YTD 2018 11
Genentech Inc, Medical Devices Deals, 2012 to YTD 2018 13
Genentech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 17
Microbiotica Enters into Collaboration Agreement with Genentech 18
Tesaro Enters into Collaboration Agreement with Genentech 19
Lodo Therapeutics Enters into Agreement with Genentech 20
Tesaro Enters into Partnership with Genentech 21
Forty Seven Enters into Agreement with Genentech 22
Syndax Pharma Enters into Agreement with Genentech 23
DiCE Molecules Enters into Research Agreement with Genentech 24
Biothera Pharma Enters into Collaboration Agreement with Genentech 25
Epizyme Enters into Agreement with Genentech 26
Inovio Pharma Enters into Agreement with Genentech 27
Amunix Operating Enters into R&D Agreement with Genentech 28
BioNTech Enters into Agreement with Genentech 29
Gradalis Enters into Agreement with Genentech 30
G1 Therapeutics Enters into Agreement with Genentech 31
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 32
Charles River Laboratories International Extends Agreement with Genentech 33
BioLineRx Enters into Agreement with Genentech 34
Epizyme Enters into Agreement with Genentech 35
Astex Pharma Enters into Agreement with Genentech 36
Clovis Oncology Enters into Agreement with Genentech 37
Janssen Research & Development Enters into Agreement with Genentech 38
Kite Pharma Enters into Agreement with Genentech 39
PeptiDream Enters into Agreement with Genentech 40
Corvus Pharma Expands its Agreement with Genentech 41
Immune Design Enters into Clinical Trial Collaboration with Genentech 42
WaferGen Bio-systems Enters into Research Agreement with Genentech 43
23andMe Partners with Genentech 44
Genentech Enters into Research Agreement with NewLink Genetics 45
Ascendis Pharma Enters Into Collaboration Agreement with Genentech 46
RQx Pharma Enters Into Drug Discovery Agreement With Genentech 47
Ensemble Therapeutics Enters Into Drug Discovery Agreement With Genentech 48
Constellation Pharma Enters Into Co-Development Agreement With Genentech 49
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 50
Genentech Enters into Licensing Agreement with Kineta Chronic Pain 51
Dermira Enters into Licensing Agreement with F. Hoffmann-La Roche and Genentech for Lebrikizumab 52
Mylan Enters into Licensing Agreement with Genentech and Roche 54
Genentech Enters into Licensing Agreement with Novimmune 55
Novogen Enters into Licensing Agreement with Genentech for GDC-0084 56
Genentech to Enter into Licensing Agreement with Hanmi Pharma 57
Denali Therapeutics Enters Into Licensing Agreement With Genentech 58
Genentech Enters into Licensing Agreement with Nimbus Therapeutics 59
Genentech Expands Licensing Agreement with Arvinas 60
Genentech Enters into Licensing Agreement with Almac Discovery 61
Phylogica Extends Licensing Agreement with Genentech 62
Genentech to Terminate Licensing Agreement with NewLink Genetics for NLG919 63
Coherus BioSciences Enters into Licensing Agreement with Genentech 65
Immunocore Enters Into Licensing And Research Agreement With Genentech For Cancer Drugs 66
Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 67
Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 68
Genentech Enters into Licensing Agreement with Carmot Therapeutics 69
Afraxis Enters Into Licensing Agreement With Genentech 70
AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 71
Noritsu Koki to Acquire 64.7% Stake in Genentech for USD27 Million 73
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 74
Genentech Inc, Key Competitors 75
Genentech Inc, Key Employees 76
Genentech Inc, Other Locations 77

List of Figures
Genentech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Genentech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Genentech Inc, Medical Devices Deals, 2012 to YTD 2018 13

★海外企業調査レポート[Genentech Inc：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • RCR Tomlinson Ltd (RCR)：企業の財務・戦略的SWOT分析
    RCR Tomlinson Ltd (RCR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Japan Foods Co Ltd：企業の戦略・SWOT・財務分析
    Japan Foods Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Japan Foods Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Richelieu Hardware Ltd：企業の戦略・SWOT・財務情報
    Richelieu Hardware Ltd - Strategy, SWOT and Corporate Finance Report Summary Richelieu Hardware Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • National Australia Bank Group Ltd：戦略・SWOT・企業財務分析
    National Australia Bank Group Ltd - Strategy, SWOT and Corporate Finance Report Summary National Australia Bank Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Stemcor Global Holdings Ltd：企業の戦略・SWOT・財務情報
    Stemcor Global Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Stemcor Global Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Total SA (FP)：企業の財務・戦略的SWOT分析
    Total SA (FP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • CornerStone Research & Development Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary CornerStone Research & Development Inc (Capstone Nutrition), doing business as Capstone Nutrition Inc is a developer and manufacturer of nutrition products. The company offers development, production and packaging of capsule, tablet, and powder products. It offers product ideation, formulati …
  • Bio-Alternative Medical Devices Ltd：企業の製品パイプライン分析2018
    Summary Bio-Alternative Medical Devices Ltd (Bio AMD), a subsidiary of Bio-AMD Inc, is a medical device company that designs, develops, and markets point of care medical diagnostic products. The company offers products such as blood coagulation monitor, digital strip reader, and magnetic immunoassay …
  • Palatin Technologies Inc (PTN)：製薬・医療：M&Aディール及び事業提携情報
    Summary Palatin Technologies Inc (Palatin) is a biopharmaceutical company that undertakes the development of targeted, receptor-specific peptide therapeutics. The company’s development programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor sys …
  • Fugro NV (FUR)：企業の財務・戦略的SWOT分析
    Fugro NV (FUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Sanquin Blood Supply Foundation：医療機器：M&Aディール及び事業提携情報
    Summary Sanquin Blood Supply Foundation (Sanquin) is a provider of blood bank and diagnostic services, plasma derived products, tissues and cells and reagents. It offers blood-related lab tests for hospitals, blood banks, obstetricians practices, pharmaceutical companies, insurance organizations, an …
  • Lycamobile UK Limited：企業の戦略的SWOT分析
    Lycamobile UK Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Emirates NBD Bank：企業の戦略・SWOT・財務分析
    Emirates NBD Bank - Strategy, SWOT and Corporate Finance Report Summary Emirates NBD Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • NetEnt AB (NET B)：企業の財務・戦略的SWOT分析
    Summary NetEnt AB (NetEnt), formerly Net Entertainment NE AB, is a gaming solution provider. The company offers netent live, pooled jackpots, branded games, casinomodule, back office, touch, live casino and extend. It provides services such as business intelligence, regulated markets, iGaming media …
  • Eloxx Pharmaceuticals Inc (ELOX)：企業の財務・戦略的SWOT分析
    Eloxx Pharmaceuticals Inc (ELOX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Evolving Systems Inc (EVOL)：企業の財務・戦略的SWOT分析
    Summary Evolving Systems Inc (Evolving Systems) is a technology company that provides development, delivering and supporting technologies and vendor independent software solutions. The company offers software solutions such as real-time lifecycle marketing, dynamic sim allocation, tertio service act …
  • Prime Polymer Co Ltd：企業の戦略的SWOT分析
    Prime Polymer Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Cooper Tire & Rubber Co (CTB)：企業の財務・戦略的SWOT分析
    Cooper Tire & Rubber Co (CTB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Flexera Software LLC：企業の戦略的SWOT分析
    Flexera Software LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (874)：企業の財務・戦略的SWOT分析
    Summary Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (Guangzhou Baiyunshan Pharmaceutical) is a manufacturer of herbal medicine, chemical raw material medicine and preparation, biological medicine, and health products. The company also offers herbal tea, Chinese and Western medicine, intermed …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆